StockData
PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

Penumbra Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$322.41+1.55 (+0.48%)

Close on Oct 19, 2026

Market cap
$12.76B
P/E (TTM)
79.2
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 30, 2026After market close$390.00M$0.88–
Q1 FY2026
Ended Mar 31, 2026
May 6, 2026After market close$374.80M$0.82–
Q4 FY2025
Ended Dec 31, 2025
Jan 15, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025After market close$354.70M$1.17$0.97
Q2 FY2025
Ended Jun 30, 2025
Jul 29, 2025After market close$339.50M$1.15$0.86
Q1 FY2025
Ended Mar 31, 2025
Apr 23, 2025After market close$324.10M$1.00$0.83
Q4 FY2024
Ended Dec 31, 2024
Feb 18, 2025After market close$315.50M$0.86$0.97
Q3 FY2024
Ended Sep 30, 2024
Oct 30, 2024After market close$301.00M$0.75$0.85
Q2 FY2024
Ended Jun 30, 2024
Jul 30, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Feb 22, 2024After market close–––

Company guidance

Outlook given with results on Nov 5, 2025, compared with the previous outlook

MeasurePeriodGuidancevs. prior
U.S. Thrombectomy growth202520% to 21% growthMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Penumbra filed with the SEC